

RECEIVED  
CENTRAL FAX CENTER

OCT 16 2006

Atty. Dkt. No. 041673-2115

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application. For ease of reference, a copy of the claims set without markups is appended hereto.

Listing of Claims:

1. (Currently Amended) A method for delivery of a therapeutic neurotrophin to targeted ~~neurotrophin-receptive neurons~~ receptive thereto in the mammalian brain ~~to stimulate growth, or sustain activity therein,~~ the method comprising directly delivering a neurotrophin encoding transgene viral expression vector into up to 10 two or more delivery sites in the brain, wherein each delivery site is no more than about 10 mm from another delivery site, and wherein further expression of the therapeutic neurotrophin leads to stimulation of growth, sustains activity, or ameliorates defects, disease or damage, in said targeted neurons.
2. (Previously Cancelled).
3. (Original) The method according to Claim 1, wherein the viral expression vector is an adenovirus.
4. (Original) The method according to Claim 1, wherein the viral expression vector is an adeno-associated virus.
5. (Original) The method according to Claim 1, wherein the viral expression vector is a lentivirus.
6. (Original) The method according to Claim 1, wherein the viral expression vector is HIV-1.
7. (Currently Amended) The method according to Claim 1 2, wherein the viral expression vector is provided in neurotrophic composition is a pharmaceutically acceptable fluid composition having a concentration of neurotrophin encoding viral particles in the range from  $10^{10}$  to  $10^{15}$  particles per ml of neurotrophic composition fluid.
8. (Currently Amended) The method according to Claim 7, wherein from 2.5  $\mu$ l to 25  $\mu$ l of the ~~neurotrophic~~ composition is delivered to each delivery site.
9. (Previously Cancelled).
10. (Previously Cancelled).

Atty. Dkt. No. 041673-2115

11. (Currently Amended) The method according to Claim 1 wherein the treated mammal is a human and the neurotrophin transgene encodes is a human neurotrophin.
12. (Original) The method according to Claim 11 wherein the neurotrophin is selected from the group of neurotrophins consisting of human beta nerve growth factor ( $\beta$ -NGF); human neurotrophin 3 (NT-3); glial cell line-derived neurotrophic factor (GDNF); brain-derived neurotrophic factor (BDNF) and neurtotrophin-4/5 (NT-4/5).
13. (Previously Cancelled).
14. (Original) The method according to Claim 1 wherein the delivery sites are intraparenchymal.
15. (Original) The method according to Claim 1 wherein the delivery sites are within the Ch4 region of the cholinergic basal forebrain.
16. (Cancelled)
17. (Currently Amended) The method according to Claim 11 wherein the ameliorated growth or increase in neuronal activity ameliorates disease in the human is Alzheimer's disease in the human.
18. (Currently Amended) The method according to Claim 11 wherein the ameliorated growth or increase in neuronal activity ameliorates disease in the human is Parkinson's Disease in the human.
19. (New) The method according to Claim 1, wherein each delivery site is chosen so diffusion of the expressed neurotrophin brings it into contact with other targeted neurons.